The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model
Current Eye Research, cilt.36, sa.11, ss.1005-1013, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 11
- Basım Tarihi: 2011
- Doi Numarası: 10.3109/02713683.2011.601840
- Dergi Adı: Current Eye Research
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1005-1013
- Anahtar Kelimeler: Bevacizumab, Corneal neovascularization, Pegaptanib, Ranibizumab, Trastuzumab
- Van Yüzüncü Yıl Üniversitesi Adresli: Hayır
Özet
Aim and scope: To investigate the inhibitory effect of subconjunctival application of VEGF antibodies bevacizumab, ranibizumab, pegaptanib, and HER2 antibody trastuzumab on corneal neovascularization in a rat model of experimental corneal neovascularization. Material and method: Thirty male Wistar albino rats were included in the study. A chemical burn was induced in central cornea of one eye of the rats by a 75% silver nitrate and 25% potassium nitrate stick. Rats were randomly divided into five groups so that each group contained 6 subjects. Right after the chemical burn, 0.1ml serum physiologic was injected subconjuctivally in control group (group 1). 1.25mg/0.05ml bevacizumab was injected in group 2; 1.2mg/0.1ml trastuzumab was injected in group 3; 0.5mg/0.05ml ranibizumab was injected in group-4; and 0.3mg/0.1ml pegaptanib was injected in group 5. On the 8th day of the experiment, rat corneas were photographed by digital photo-camera. Later, eyes of the sacrificed rats were enucleated and corneal speciements were histopathologically analyzed. The percentages of neovascularization on corneal photographs were examined with digital image analysis. Results: The percentage of corneal neovascularization in all treatment groups was found to be significantly lower than the control group (p<0.05). Bevacizumab was found to be more effective than all other agents (p<0.05). While the degree of inflammation and vascularization in bevacizumab and trastuzumab groups were significantly lower than the control group (p<0.05), the difference was not significant in ranibizumab and pegaptanib groups (p>0.05). In all treatment groups, fibroblast intensity was significantly lower than the control group. In terms of corneal thickness, no significant difference was observed between treatment and control groups (p>0.05). Conclusion: Bevacizumab, ranibizumab, pegaptanib, and trastuzumab were found effective for the inhibition of corneal NV. In our study we detected that the most effective agent was bevacizumab. © 2011 Informa Healthcare USA, Inc.